Aortic stenosis: insights on pathogenesis and clinical implications

Patrizia Carità, Giuseppe Coppola, Giuseppina Novo, Giuseppa Caccamo, Marco Guglielmo, Fabio Balasus, Salvatore Novo, Sebastiano Castrovinci, Marco Moscarelli, Khalil Fattouch, Egle Corrado, Patrizia Carità, Giuseppe Coppola, Giuseppina Novo, Giuseppa Caccamo, Marco Guglielmo, Fabio Balasus, Salvatore Novo, Sebastiano Castrovinci, Marco Moscarelli, Khalil Fattouch, Egle Corrado

Abstract

Aortic stenosis (AS) is a common valvular heart disease in the Western populations, with an estimated overall prevalence of 3% in adults over 75 years. To understand its patho-biological processes represents a priority. In elderly patients, AS usually involves trileaflet valves and is referred to as degenerative calcific processes. Scientific evidence suggests the involvement of an active "atherosclerosis-like" pathogenesis in the initiation phase of degenerative AS. To the contrary, the progression could be driven by different forces (such as mechanical stress, genetic factors and interaction between inflammation and calcification). The improved understanding presents potentially new therapeutic targets for preventing and inhibiting the development and progression of the disease. Furthermore, in clinical practice the management of AS patients implies the evaluation of generalized atherosclerotic manifestations (i.e., in the coronary and carotid arteries) even for prognostic reasons. In counselling elderly patients, the risk stratification should address individual frailty beyond the generic risk scores. In these regard, the co-morbidities, and in particular those linked to the global atherosclerotic burden, should be carefully investigated in order to define the risk/benefit ratio for invasive treatment strategies. We present a detailed overview of insights in pathogenesis of AS with possible practical implications.

Keywords: Atherosclerosis; Clinical implications; Degenerative aortic stenosis; Pathogenesis; The elderly.

References

    1. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231–43.
    1. Eveborn GW, Schimmer H, Heggelund G, et al. The evolving epidemiology of valvular aortic stenosis: the Tronso study. Heart. 2013;99:396–400.
    1. Otto CM, Prendergast B. Aortic-valve stenosis - from patients at risk to severe valve obstruction. N Engl J Med. 2014;371:744–756.
    1. Mathieu P, Boulanger MC. Basic mechanisms of calcific aortic valve disease. Can J Cardiol. 2014;30:982–993.
    1. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Am J Cardiol. 1997;29:630–634.
    1. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997;95:2262–2270.
    1. Pomerance A, Darby Aj, Hodkinson HM. Valvular calcification in the elderly: possible pathogenic factors. J Gerontol. 1978;33:672–675.
    1. Wierzbicki A, Shetty C. Aortic stenosis: an atherosclerotic disease? J Heart Valve Dis. 1999;8:416–423.
    1. Agmon Y, Khandheria BK, Meissner I. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol. 2001;38:827e34.
    1. Mohler ER, Sheridan MJ, Nichols R, et al. Development and progression of aortic valve stenosis: atherosclerosis risk factors—a causal relationship? A clinical morphologic study. Clin Cardiol. 1991;14:995–999.
    1. Otto CM, Knusisto J, Reichenbach D, et al. Characterization of the early lesion of degenerative valvular aortic stenosis; historical and immunohistochemical studies. Circulation. 1994;90:844–853.
    1. Carabello BA. Introduction to aortic stenosis. Circ Res. 2013;113:179–185.
    1. Novo G, Fazio G, Visconti C, et al. Atherosclerosis, degenerative aortic stenosis and statins. Curr Drug Targets. 2011;12:115–121.
    1. Mathieu P, Boulanger MC, Bouchareb R. Molecular biology of calcific aortic valve disease: towards new pharmacological therapies. Expert Rev Cardiovasc Ther. 2014;12:851–862.
    1. Otto CM, O'Brien KD. Why is there discordance between calcific aortic stenosis and coronary artery disease? Heart. 2001;85:601–602.
    1. Fried LP, Borhani NO, Enright P, et al. The cardiovascular health study: design and rationale. Ann Epidemiol. 1991;1:263–276.
    1. Vongpromek R, Bos S, Ten Kate GJ, et al. Lipoprotein (a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Intern Med. 2015;278:166–173.
    1. Le Quang K, Bouchareb R, Lachance D, et al. Early development of calcific aortic valve disease and left ventricular hypertrophy in a mouse model of combined dyslipidemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34:2283–2291.
    1. Pohle K, Mäffert R, Ropers D, et al. Progression of aorticvalve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104:1927–1932.
    1. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–2397.
    1. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356.
    1. Capoulade R, Côté N, Mathieu P, et al. Circulating levels of matrix gla protein and progression of aortic stenosis: a substudy of the Aortic Stenosis Progression Observation: Measuring Effects of rosuvastatin (ASTRONOMER) trial. Can J Cardiol. 2014;30:1088–1095.
    1. Novo G, Noto D, Averna M, et al. Statin therapy in patients with aortic stenosis after the ASTRONOMER trial: is there still any space? Intern Emerg Med. 2012;7:S35–S36.
    1. Choi KJ, Tsomidou C, Lerakis S, et al. Lipid interventions in aortic valvular disease. Am J Med Sci. 2015;350:313–319.
    1. Arsenault BJ, Boekholdt SM, Mora S, et al. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL) Am J Cardiol. 2014;113:1378–1382.
    1. Pawade TA, Newby DE, Dweck MR. Calcification in aortic stenosis: the skeleton key. J Am Coll Cardiol. 2015;66:561–577.
    1. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117:2938–2948.
    1. Clavel MA, Pibarot P, Messika-Zeitoun D, et al. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. J Am Coll Cardiol. 2014;64:1202–1213.
    1. Pawade TA, Newby DE. Treating aortic stenosis: arresting the snowball effect. Expert Rev Cardiovasc Ther. 2015;13:461–463.
    1. Demer LL. A skeleton in the atherosclerosis closet. Circulation. 1995;92:2029–2032.
    1. Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol. 2007;171:1407–1418.
    1. Parisi V, Leosco D, Ferro G. The lipid theory in the pathogenesis of calcific aortic stenosis. Nutr Metab Cardiovasc Dis. 2015;25:519–525.
    1. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–319.
    1. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004;36:57–66.
    1. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–1268.
    1. Sainger R, Grau JB, Branchetti E, et al. Comparison of transesophageal echocardiographic analysis and circulating biomarker expression profile in calcific aortic valve disease. J Heart Valve Dis. 2013;22:156–165.
    1. Ferrari G, Sainger R, Beckmann E, et al. Validation of plasma biomarkers in degenerative calcific aortic stenosis. J Surg Res. 2010;163:12–17.
    1. Dimitrow PP, Jawień M, Gackowski A. The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. J Heart Valve Dis. 2011;20:18–22.
    1. Persy V, D'haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med. 2009;15:405–416.
    1. Bossé Y, Miqdad A, Fournier D, et al. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet. 2009;2:489–498.
    1. Ortlepp J R, HoVmann R, Ohme F, et al. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart. 2001;85:635–663.
    1. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765.
    1. Sterbakova G, Vyskocil V, Linhartova K. Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease: a pilot retrospective study. Cardiology. 2010;117:184–189.
    1. Innasimuthu AL, Katz WE. Effect of bisphosphonates on the progression of degenerative aortic stenosis. Echocardiography. 2011;8:1–7.
    1. Skolnick AH, Osranek M, Formica P, et al. Osteoporosis treatment and progression of aortic stenosis. Am J Cardiol. 2009;104:122–124.
    1. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem. 2004;4:711–719.
    1. Aksoy O, Cam A, Goel SS, et al. Do bisphosphonates slow the progression of aortic stenosis? J Am Coll Cardiol. 2012;59:1452–1459.
    1. Elmariah S, Delaney JA, O'Brien KD, et al. Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (The Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol. 2010;56:1752–1759.
    1. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961–2978.
    1. Conte L, Rossi A, Cicoira M, et al. Aortic valve sclerosis: a marker of significant obstructive coronary artery disease in patients with chest pain? J Am Soc Echocardiogr. 2007;20:703–708.
    1. Tansuphaswadikul S, Silaruks S, Lehmongkol R, et al. Frequency of angina pectoris and coronary artery disease in severe isolated valvular aortic stenosis. J Med Assoc Thai. 1999;82:140–149.
    1. García Rubira JC, Romero Chacón D, Naranjo D, et al. Prevalence of coronary disease in patients with aortic stenosis. Rev Esp Cardiol. 1992;45:427–431.
    1. Cho EJ, Park SJ, Chang SA, et al. Incidence of coronary artery disease before valvular surgery in isolated severe aortic stenosis. Chin Med J (Engl) 2014;127:3963–3969.
    1. Utsunomiya H, Yamamoto H, Kunita E, et al. Combined presence of aortic valve calcification and mitral annular calcification as a marker of the extent and vulnerable characteristics of coronary artery plaque assessed by 64-multidetector computed tomography. Atherosclerosis. 2010;213:166–172.
    1. Pressman GS, Crudu V, Parameswaran-Chandrika A, et al. Can total cardiac calcium predict the coronary calcium score? Int J Cardiol. 2011;146:202–206.
    1. Fusini L, Mirea O, Tamborini G, et al. Incidence and severity of atherosclerotic cardiovascular artery disease in patients undergoing TAVI. Int J Cardiovasc Imaging. 2015;31:975–985.
    1. Novo S, Visconti CL, Amoroso GR, et al. Asymptomatic carotid lesions add to cardiovascular risk prediction. Eur J Cardiovasc Prev Rehabilit. 2010;17:514–518.
    1. Novo S, Carità P, Corrado E, et al. Preclinical carotid atherosclerosis enhances the global cardiovascular risk and increases the rate of cerebro- and cardiovascular events in a five-year follow-up. Atherosclerosis. 2010;211:287–290.
    1. Kabłak-Ziembicka A, Przewłocki T, Mura A, et al. Evaluation of carotid intima-media thickness in patients with aortic valve calcifications. Acta Cardiol. 2004;59:199–200.
    1. Novo G, Guarneri FP, Ferro G, et al. Association between asymptomatic carotid atherosclerosis and degenerative aortic stenosis. Atherosclerosis. 2012;223:519–522.
    1. Sgorbini L, Scuteri A, Leggio M, et al. Association of mitral annulus calcification, aortic valve calcification with carotid intima media thickness. Cardiovasc Ultrasound. 2004;2:19.
    1. Antonini-Canterin F, Leiballi E, Capanna M. Association between carotid and coronary artery disease in patients with aortic valve stenosis: an angiographic study. Angiology. 2009;60:596–600.
    1. Kablak-Ziembicka A, Przewlocki T, Tracz W, Podolec P, et al. Prognostic value of carotid intima-media thickness in detection of coronary atherosclerosis in patients with calcified aortic valve stenosis. J Ultrasound Med. 2005;24:461–467.
    1. Belhassen L, Carville C, Pelle G, et al. Evaluation of carotid artery and aortic intima-media thickness measurements for exclusion of significant coronary atherosclerosis in patients scheduled for heart valve surgery. J Am Coll Cardiol. 2002;39:1139–1144.
    1. Sawhney N, Hassankhani A, Greenberg BH. Calcific aortic stenosis in the elderly: a brief overview. Am J Geriatr Cardiol. 2003;12:178–182.
    1. Ross J, Braunwald E. Aortic stenosis. Circulation. 1968;38:61–67.
    1. Bouma BJ, Van den Brink RB, Van der Meulen JH, et al. To operate or not on elderly patients with aortic stenosis: the decision and its consequences. Heart. 1999;82:143–148.
    1. Kato M, Yamamoto K. Clinical characteristics of elderly patients with aortic stenosis. J Echocardiogr. 2015;13:134–140.
    1. Abdul-Hamid AR, Mulley GP. Why do so few older people with aortic stenosis have valve replacement surgery? Age Ageing. 1999;28:261–264.
    1. O'Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeon 2008 cardiac surgery risk models: part 2 – isolated valve surgery. Ann Thorac Surg. 2009;88:S23–S42.
    1. Logeais L, Langanay T, Roussin R, et al. Surgery for aortic stenosis in elderly patients. A study of surgical risks and predictive factors. Circulation. 1994;90:2891–2898.
    1. Mistiaen W, Van Cauwelaert P, Muylaert P, et al. Risk factors and survival after aortic valve replacement in octagenarios. J Heart Valve Dis. 2004;13:538–544.
    1. Pascual I, Muñoz-García AJ, Avanzas P, et al. Trancatheter aortic valve implantation in very elderly patients: immediate results and medium term follow-up. J Geriatr Cardiol. 2015;12:340–345.
    1. Leon MB, Smith RC, Mack MJ, et al. Transcatheter aortic valve implantation for aortic stenosis in patients who cannot undergo surgery. New Engl J Med. 2010;363:1597–1607.
    1. Smith RC, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic valve replacement in high risk patients. New Engl J Med. 2011;364:2187–2198.
    1. Kojodijojo P, Gohil N, Barker D, et al. Outcomes of elderly patients aged 80 years and over with symptomatic, severe aortic stenosis: impact of patient's choice of refusing aortic valve replacement on survival. Q I Med. 2008;101:567–573.
    1. Wendt D, Osswakd BR, Keyser K, et al. Society of thoracic surgeons score is superior to the EuroSCORE determining mortality in high risk patients undergoing isolated aortic valve replacement. Ann Thorac Surg. 2009;88:468–474.
    1. Boasi V, Casale MC, Aste M, et al. Aortic stenosis in the elderly: understanding the new therapeutic options. World J Cardiovasc Surg. 2012;2:96–107.
    1. Bakeen FG, Chu D, Rateliffe M, et al. Severe aortic stenosis in a veteran population: treatment, considerations and survival. Ann Thorac Surg. 2010;89:453–458.
    1. Soh SY, Wong DTL. Aortic stenosis and aging. OA Elderly Med. 2014;2:1.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する